ADME in CGT: How Conventional ADME Test Systems Can De-risk CGT Studies

From cancer cures to treatments for “untreatable” genetic disorders, cell and gene therapies (CGTs) are poised to revolutionize the next generation of medical care. However, evaluating the safety of these advanced therapies is critical to ensuring beneficial outcomes for patients.
Gene editing techniques like CRISPR and gene therapies that disseminate through the body systemically will encounter the liver and/or kidneys and may represent an off-target liability. Therefore, CGT developers are utilizing conventional ADME test systems, such as primary cyroplatable hepatocytes, in in vitro assays to investigate potential unforeseen properties of their therapeutics and evaluate potential safety risks.
Key concepts discussed in this webinar include:
- The potential of CGTs to present off-target liabilities.
- In vitro toxicity assays to assess potential acute off-target toxicity.
- Utilizing plated hepatocytes to assess efficiency and potential off-target effects.
- Advanced long-term hepatocyte co-cultures to assess potential chronic off target toxicity
Download a copy of the slides: info.bioivt.com/adme-cgt-wbr-reg
Submit inquiries: bioivt.com/about/contact-us
About the Presenter
Dr. Chris Bohl received his PhD from the School of Biological Sciences from the University of Nebraska - Lincoln and has been with XenoTech/BioIVT since 2014, first operating as a research scientist, then the Senior Manager of Technical Support for Products, and now a Scientific Advisor for ADMET products. Chris provides valuable guidance to scientists seeking to choose the correct test system, troubleshoot difficulties and much more.